Human PD-L1/B7-H1 DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human PD-L1/B7-H1 DuoSet ELISA, 15 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: CD274

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human PD-L1/B7-H1 DuoSet ELISA, 15 Plate

• Avelumab
• B7-H
• B7H1
• B7-H1
• B7H1PDCD1L1
• CD274 antigenMGC142294
• CD274 molecule
• CD274
• PDCD1L1
• PDCD1LG1
• PDCD1LG1MGC142296
• PDL1
• PD-L1
• PD-L1B7 homolog 1
• PDL1PDCD1 ligand 1
• programmed cell death 1 ligand 1
• Programmed death ligand 1

Background

PD-L1, also known as B7-H1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells, keratinocytes, enothelial and intestinal epithelial cells, as well as a variety of carcinomas and melanoma. PD-L1 binds to T cell B7-1/CD80 and PD-1. It suppresses T cell activation and proliferation and induces the apoptosis of activated T cells. It plays a role in the development of immune tolerance by promoting T cell anergy and enhancing regulatory T cell development. PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells and inhibits the development of Th17 cells. In cancer, PD-L1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells.

Publications for PD-L1 (DY156)(9)

Publications using DY156

• Miladinov, M;Rosic, J;Eric, K;Guzonjic, A;Jelenkovic, J;Bogavac-Stanojevic, N;Dimitrijevic, I;Kotur-Stevuljevic, J;Barisic, G; Analysis of the Prognostic Potential of Schlafen 11, Programmed Death Ligand 1, and Redox Status in Colorectal Cancer Patients International journal of molecular sciences 2023-10-11 [PMID: 37894765] (Human)
• K Krueger, Z Mayer, M Kottmaier, M Gerckens, S Boeck, P Luppa, S Holdenried Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood Biomedicines, 2022-10-11;10(10):. 2022-10-11 [PMID: 36289796] (Human)
• K Krueger, Z Mayer, M Gerckens, S Boeck, P Luppa, S Holdenried High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood Biomedicines, 2022-09-26;10(10):. 2022-09-26 [PMID: 36289665] (Human)
• M Roksandic, A Klisic, V Ceriman, J Kotur Stev, K Savic Vujo, D Mirkov, M Gajic, B Ilic, N Dimic, N Samardzic, D Jovanovic Oxidative stress and inflammation parameters-novel biomarkers for idiopathic pulmonary fibrosis European review for medical and pharmacological sciences, 2022-02-01;26(3):927-934. 2022-02-01 [PMID: 35179759] (Human)
• G Larrinaga, JD Solano-Itu, P Errarte, M Unda, A Loizaga-Ir, A Pérez-Fern, E Echevarría, A Asumendi, C Manini, JC Angulo, JI López Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma Cancers, 2021-02-07;13(4):. 2021-02-07 [PMID: 33562338] (Human)
• C Voisin, G Cauchois, L Reppel, C Laroye, L Louarn, C Schenowitz, P Sonon, I Poras, V Wang, E D Carosell, N Benkirane-, P Moreau, N Rouas-Frei, D Bensoussan, C Huselstein Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation? J Clin Med, 2020-02-04;9(2):. 2020-02-04 [PMID: 32033151] (Human)
• Jovanovic D, Roksandic Milenkovic M, Kotur Stevuljevic J, Markovic J, Ceriman V, Kontic M, Skodric Trifunovic V Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. J Thorac Dis, 2018-12-01;10(12):6660-6669. 2018-12-01 [PMID: 30746211] (Human)
• S Kruger, ML Legenstein, V Rösgen, M Haas, DP Modest, CB Westphalen, S Ormanns, T Kirchner, V Heinemann, S Holdenried, S Boeck Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer Oncoimmunology, 2017-03-31;6(5):e1310358. 2017-03-31 [PMID: 28638732] (Human)
• Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression Stem Cells, 2016-10-26;0(0):. 2016-10-26 [PMID: 27671847] (Human)

FAQs for PD-L1 (DY156). (Showing 1 - 1 of 1 FAQs).

1. What is the difference between the Quantikine and Duoset ELISA kits?
   • Our Quantikine kits are fully optimized and validated for the sample types listed on the product specific webpage and datasheet, as this can vary between kits. Each kit is supplied ready to use with one pre-coated 96-well plate, a detection antibody directly conjugated to HRP, and all other necessary reagents. These kits are ideal for researchers who want the convenience of a ready to use and optimized ELISA product. Some of these kits are also available prepackaged in larger 6 and 50 plate sizes.Our DuoSet Kits, in contrast, are ELISA development kits containing the capture and detection antibody, the mass-value calibrated standard, and streptavidin-HRP to prepare approximately 5 or 15 plates. Ancillary reagents will need to be used/purchased, and for most kits, we will recommend one of our Ancillary Reagent Kits, which contain the reagents we use ourselves in-house. DuoSet kits are validated only for cell culture supernatant samples and therefore require further development and validation for accurate measurement in more complex samples such as serum and plasma. Our DuoSet Kits offer an economical, flexible alternative for the experienced ELISA user.

Bioinformatics

• Gene Symbol: CD274